Zobrazeno 1 - 10
of 366
pro vyhledávání: '"Victor M Santana"'
Autor:
Daniel C. Moreira, Ariana Znaor, Victor M. Santana, Anastasia Dolya, Leeanna Fox Irwin, Nickhill Bhakta, Les Mery, Eva Steliarova-Foucher
Publikováno v:
JCO Global Oncology, Vol , Iss 10 (2024)
PURPOSEOne determinant of the paucity of data on childhood cancer in low- and middle-income countries is the lack of capacity to register these cases. Combining expertise of the Global Initiative for Cancer Registry Development (GICR) and St Jude Glo
Externí odkaz:
https://doaj.org/article/6a6c90e92dde447a9e96a04246cf2a3f
Autor:
Dylan E. Graetz, Thelma Velasquez, Inam Chitsike, Hadeel Halalsheh, Ana Cáceres-Serrano, Lucia Fuentes, Nester Chokwenda, Edith Matsikidze, Gia Ferrara, Tharwa Bilbeisi, Anneliese Williams, Nickhill Bhakta, Sima Jeha, Carlos Rodriguez Galindo, Jennifer W. Mack, Victor M. Santana
Publikováno v:
JCO Global Oncology, Vol , Iss 10 (2024)
PURPOSEStigma is an understudied barrier to health care acceptance in pediatric oncology. We sought to explore the stigma experience, including its impact on cancer treatment decision making, and identify strategies to mitigate stigma for patients wi
Externí odkaz:
https://doaj.org/article/7428aec3de024d96a2f4cc428bf1da0b
Autor:
John Thomas Lucas, Jr., Daniel Victor Wakefield, Michael Doubrovin, Yimei Li, Teresa Santiago, Sara Michele Federico, Thomas E. Merchant, Andrew M. Davidoff, Matthew J. Krasin, Barry L. Shulkin, Victor M. Santana, Wayne Lee Furman
Publikováno v:
Clinical and Translational Radiation Oncology, Vol 34, Iss , Pp 42-50 (2022)
Purpose: This retrospective study sought to identify predictors of metastatic site failure (MSF) at new and/or original (present at diagnosis) sites in high-risk neuroblastoma patients. Methods and materials: Seventy-six high-risk neuroblastoma patie
Externí odkaz:
https://doaj.org/article/6ade4831c50140b89f8a8b0af0478d55
Autor:
Michael W. Bishop, Paul R. Hutson, Jacquelyn A. Hank, Paul M. Sondel, Wayne L. Furman, Michael M. Meagher, Fariba Navid, Victor M. Santana
Publikováno v:
mAbs, Vol 12, Iss 1 (2020)
Hu14.18K322A is a humanized anti-GD2 monoclonal antibody with a single point mutation that reduces complement-mediated cytotoxicity, with a maximum tolerated dose (MTD) of 60 mg/m2 daily for 4 days in children with recurrent/refractory neuroblastoma.
Externí odkaz:
https://doaj.org/article/940c5599493e4765891a98b5a77da59b
Autor:
Mara Baudena, V Ramon Vallejo, Jaime Baeza, Aymen Moghli, Alejandro Valdecantos, Victor M Santana
Forest fires and extreme droughts will continue to be main disturbances in Mediterranean ecosystems, given the ongoing and projected climatic changes. In fact, an exacerbation of some aspects of their regime is expected. In this perspective, it is fu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fb89ab8e86e20ebe22f41df490716add
https://doi.org/10.5194/egusphere-egu23-9283
https://doi.org/10.5194/egusphere-egu23-9283
Autor:
Clinton F. Stewart, Burgess B. Freeman, Stacy L. Throm, K. Elaine Harstead, David M. Loeb, Jennifer Reikes Willert, Bhaskar Rao, Michael Neel, Victor M. Santana, Jianrong Wu, Shenghua Mao, Najat C. Daw, Fariba Navid, David C. Turner
Purpose: To describe sources of interindividual variability in bevacizumab disposition in pediatric patients and explore associations among bevacizumab pharmacokinetics and clinical wound healing outcomes.Experimental Design: Before tumor resection,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c735d08d71518fd443f7e25a1e9a5a5e
https://doi.org/10.1158/1078-0432.c.6521471.v1
https://doi.org/10.1158/1078-0432.c.6521471.v1
Autor:
Wayne L. Furman, Alberto S. Pappo, Victor M. Santana, Rachel C. Brennan, Shenghua Mao, Jianrong Wu, William E. Janssen, Wing Leung, Catherine Y. Ng, Aaron Shafer, Michael Meagher, Paul Hutson, Jacquelyn A. Hank, Paul M. Sondel, Barry L. Shulkin, M. Beth McCarville, Sara M. Federico
This figure demonstrates the relationship between prior treatment with chimeric or humanized 14.18 K322A antibody and A) the area under the concentration curve for the antibody (AUC); B elimination half-life of the antibody (T1/2 Beta); and C) the hi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9dda4536ff96c433e250a2f403355bb7
https://doi.org/10.1158/1078-0432.22468175.v1
https://doi.org/10.1158/1078-0432.22468175.v1
Autor:
Wayne L. Furman, Alberto S. Pappo, Victor M. Santana, Rachel C. Brennan, Shenghua Mao, Jianrong Wu, William E. Janssen, Wing Leung, Catherine Y. Ng, Aaron Shafer, Michael Meagher, Paul Hutson, Jacquelyn A. Hank, Paul M. Sondel, Barry L. Shulkin, M. Beth McCarville, Sara M. Federico
Box and whisker plot showing absolute NK cells per mm3 in samples. NK cells were identified by flow cytometry as CD14 negative, CD56 positive, CD3 negative and percentage of total WBC was computed from flow cytometry results. Absolute WBC count was o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c62a93dddc4f296d3df3b810cfbce1b0
https://doi.org/10.1158/1078-0432.22468169.v1
https://doi.org/10.1158/1078-0432.22468169.v1
Autor:
Clinton F. Stewart, Burgess B. Freeman, Stacy L. Throm, K. Elaine Harstead, David M. Loeb, Jennifer Reikes Willert, Bhaskar Rao, Michael Neel, Victor M. Santana, Jianrong Wu, Shenghua Mao, Najat C. Daw, Fariba Navid, David C. Turner
PDF file - 200K, Supplementary Table 1. Comparison of predictive performance for model parameterizations A, (B), and C (with IBW covariate) Supplemental Figure 1. The base structural bevacizumab model consisted of a two compartment model parameterize
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b2018329160909b9d070253b4a6cefe
https://doi.org/10.1158/1078-0432.22448723
https://doi.org/10.1158/1078-0432.22448723
Autor:
Wayne L. Furman, Alberto S. Pappo, Victor M. Santana, Rachel C. Brennan, Shenghua Mao, Jianrong Wu, William E. Janssen, Wing Leung, Catherine Y. Ng, Aaron Shafer, Michael Meagher, Paul Hutson, Jacquelyn A. Hank, Paul M. Sondel, Barry L. Shulkin, M. Beth McCarville, Sara M. Federico
Human anti-human antibody (HAHA) level and peak hu14.18K322A serum level by course and prior antibody therapy.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::120d7121dd373ab23a3e06c8088d7313
https://doi.org/10.1158/1078-0432.22468163
https://doi.org/10.1158/1078-0432.22468163